News

Terumo Health Outcomes Announces Distribution Agreement for Caretaker Medical’s VitalStream® Non-Invasive Hemodynamic Monitoring

Terumo Health Outcomes (THO), a division of Terumo Interventional Systems (TIS), today announced a new U.S. distribution agreement with Caretaker Medical to offer Caretaker Medical’s VitalStream wearable hemodynamic monitoring platform to hospitals nationwide. This agreement is yet another step in THO’s continued effort to bring forward-looking technologies to cardiovascular care teams seeking smarter, more efficient ways to monitor patient status and act sooner in the care process.

“We’re excited to partner with Terumo Health Outcomes to deliver impactful solutions for the early identification and improved treatment of shock and heart failure,” said Jeff Pompeo, CEO, Caretaker Medical. “Our VitalStream platform’s capability to deliver real-time, beat-by-beat physiological data – including continuous blood pressure and hemodynamics through a comfortable, non-invasive wearable – is central to this.”

Together, THO and Caretaker Medical are enabling clinicians to detect changes sooner and respond with confidence by eliminating invasive lines and bulky wires, especially in high-acuity cardiovascular settings like cath labs and cardiac step-down units – where timely and accurate intervention for these conditions is critical.

“Clinicians need reliable, non-invasive options for continuous monitoring, particularly in settings where invasive lines aren’t feasible or desired,” said Ghada Farah, President of Terumo Interventional Systems, Cardiac and Vascular Company at Terumo. “Caretaker’s VitalStream technology fits our mission of delivering tools that support earlier intervention and more informed decisions, while also helping hospitals improve clinical workflows and patient safety.”

THO is a division of TIS, which offers a portfolio of high-quality interventional devices that complement the predictive insights offered by THO’s ePRISM platform. While ePRISM assists clinicians in identifying patient risk and optimizing treatment strategies, the advanced tools from TIS support procedural efficiency, contributing to improved patient outcomes. This combination assists clinicians to make more informed decisions, facilitating smoother procedures and potentially reducing hospital costs and recovery times. Learn more at www.terumohealthoutcomes.com.

 

Read more here.

Recent News

03/19/2026

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing

03/18/2026

Phlow Corp. Appoints Dawn Von Rohr as Chief Operating Officer to Advance Domestic Pharmaceutical Manufacturing

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO). Von Rohr will oversee Phlow’s operations, manufacturing execution, and strategic growth initiatives as the company continues expanding its advanced pharmaceutical development and manufacturing infrastructure in the United States to

03/17/2026

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like